TNF and psoriasis: The frequencies of psoriasis reports between the TNF inhibitors ranged from 0.29 to 1.90%: certolizumab pegol 1.90%, adalimumab 1.16%, golimumab 0.69%, infliximab 0.52%, and etanercept 0.29% (Fig. 1).